OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia
Emre Durcan, Serbay Özkan, Halil İbrahim Saygı, et al.
Journal of Diabetes (2022) Vol. 14, Iss. 4, pp. 236-246
Open Access | Times Cited: 14
Emre Durcan, Serbay Özkan, Halil İbrahim Saygı, et al.
Journal of Diabetes (2022) Vol. 14, Iss. 4, pp. 236-246
Open Access | Times Cited: 14
Showing 14 citing articles:
Canagliflozin Attenuates Podocyte Inflammatory Injury through Suppressing the TXNIP/NLRP3 Signaling Pathway in Diabetic Kidney Disease Mice
Siyu Li, Jiawen Wang, Ying Chen, et al.
Inflammation (2025)
Open Access
Siyu Li, Jiawen Wang, Ying Chen, et al.
Inflammation (2025)
Open Access
Therapeutic potential of conditioned medium obtained from deferoxamine preconditioned umbilical cord mesenchymal stem cells on diabetic nephropathy model
Serbay Özkan, Başak Işıldar, Merve Erçin, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 21
Serbay Özkan, Başak Işıldar, Merve Erçin, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 21
Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
Gilda M. Portalatin, Irene Hong‐McAtee, Anna Burgner, et al.
Frontiers in Pediatrics (2025) Vol. 13
Open Access
Gilda M. Portalatin, Irene Hong‐McAtee, Anna Burgner, et al.
Frontiers in Pediatrics (2025) Vol. 13
Open Access
Podocyturia an emerging biomarker for kidney injury
Hanna Czeczot, Hady El Etry, Maroun Ibrahim, et al.
BMC Nephrology (2025) Vol. 26, Iss. 1
Open Access
Hanna Czeczot, Hady El Etry, Maroun Ibrahim, et al.
BMC Nephrology (2025) Vol. 26, Iss. 1
Open Access
Renal intrinsic cells remodeling in diabetic kidney disease and the regulatory effects of SGLT2 Inhibitors
Wenwen Guo, Han Li, Yixuan Li, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115025-115025
Open Access | Times Cited: 9
Wenwen Guo, Han Li, Yixuan Li, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115025-115025
Open Access | Times Cited: 9
Non-linear association of fasting C-peptide and uric acid levels with renal dysfunction based on restricted cubic spline in patients with type 2 diabetes: A real-world study
Lu Chen, Yifei Hu, Yongjun Ma, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 7
Lu Chen, Yifei Hu, Yongjun Ma, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 7
Research progress of natural active compounds on improving podocyte function to reduce proteinuria in diabetic kidney disease
Le Gong, Rui Wang, Xinyu Wang, et al.
Renal Failure (2023) Vol. 45, Iss. 2
Open Access | Times Cited: 7
Le Gong, Rui Wang, Xinyu Wang, et al.
Renal Failure (2023) Vol. 45, Iss. 2
Open Access | Times Cited: 7
Visceral adipose tissue and risk of diabetic nephropathy: A Mendelian randomization study
Min Tao, Guanghong Zhou, Jing Liu, et al.
Diabetes Research and Clinical Practice (2024) Vol. 209, pp. 111586-111586
Closed Access | Times Cited: 2
Min Tao, Guanghong Zhou, Jing Liu, et al.
Diabetes Research and Clinical Practice (2024) Vol. 209, pp. 111586-111586
Closed Access | Times Cited: 2
A new perspective on proteinuria and drug therapy for diabetic kidney disease
Ruimin Zhang, Qian Wang, Yaqing Li, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Ruimin Zhang, Qian Wang, Yaqing Li, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes
Xue Li, Qiong Li, Xinying Jiang, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
Xue Li, Qiong Li, Xinying Jiang, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease
Tian Gan, Yi Song, Feng Guo, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 11, pp. 10915-10924
Closed Access | Times Cited: 4
Tian Gan, Yi Song, Feng Guo, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 11, pp. 10915-10924
Closed Access | Times Cited: 4
A non-linear association between low-density lipoprotein cholesterol and the risk of diabetic kidney disease in patients with type 2 diabetes in China
Xi Xiang, Guangming Chen, Yongjun Ma, et al.
Preventive Medicine Reports (2024) Vol. 45, pp. 102840-102840
Open Access
Xi Xiang, Guangming Chen, Yongjun Ma, et al.
Preventive Medicine Reports (2024) Vol. 45, pp. 102840-102840
Open Access
Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort Study in Korea
Ha Young Jang, In‐Wha Kim, Jung Mi Oh
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2394-2394
Open Access | Times Cited: 1
Ha Young Jang, In‐Wha Kim, Jung Mi Oh
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2394-2394
Open Access | Times Cited: 1
